Your browser doesn't support javascript.
loading
IL-36 antagonism blunts the proliferation and migration of oral squamous cell carcinoma cells.
Li, Zihui; Zhang, Xiaoxin; Li, Ke; Li, Fuyan; Kou, Jiahao; Wang, Yuhan; Wei, Xiaoyue; Sun, Yawei; Jing, Yue; Song, Yuxian; Yu, QiuYa; Yu, Haijia; Wang, Shuai; Chen, Shi; Wang, Yangtin; Xie, Simin; Zhu, Xiangyang; Zhan, Yifan; Sun, Guowen; Ni, Yanhong.
Afiliação
  • Li Z; Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China; Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Zhang X; Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Li K; Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Li F; Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Kou J; Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Wang Y; Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Wei X; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
  • Sun Y; Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Jing Y; Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Song Y; Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Yu Q; Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Yu H; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
  • Wang S; Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Chen S; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
  • Wang Y; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
  • Xie S; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
  • Zhu X; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China.
  • Zhan Y; Drug Discovery, Shanghai Huaota Biopharmaceutical Co. Ltd., Shanghai, China. Electronic address: yifan.zhan@huabobio.com.
  • Sun G; Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Electronic address: guowensun@nju.edu.cn.
  • Ni Y; Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Electronic address: Yanhong.Ni@nju.edu.cn.
Cell Signal ; 117: 111096, 2024 05.
Article em En | MEDLINE | ID: mdl-38346528
ABSTRACT
IL-36 is known to mediate inflammation and fibrosis. Nevertheless, IL-36 signalling axis has also been implicated in cancer, although understanding of exact contribution of IL-36 to cancer progression is very limited, partly due to existence of multiple IL-36 ligands with agonistic and antagonistic function. Here we explored the role of IL-36 in oral squamous cell carcinoma (OSCC). Firstly, we analyzed expression of IL-36 ligands and receptor and found that the expression of IL-36γ was significantly higher in head and neck cancer (HNSCC) than that of normal tissues, and that the high expression of IL-36γ predicted poor clinical outcomes. Secondly, we investigated the direct effect of IL-36γ on OSCC cells and found that IL-36γ stimulated proliferation of OSCC cells with high expression of IL-36R expression. Interestingly, IL-36γ also promoted migration of OSCC cells with low to high IL-36R expression. Critically, both proliferation and migration of OSCC cells induced by IL-36γ were abrogated by anti-IL-36R mAb. Fittingly, RNA sequence analysis revealed that IL-36γ regulated genes involved in cell cycle and cell division. In summary, our results showed that IL-36γ can be a tumor-promoting factor, and targeting of IL-36R signalling may be a beneficial targeted therapy for patients with abnormal IL-36 signalling.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Bucais / Carcinoma de Células Escamosas / Neoplasias de Cabeça e Pescoço Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Bucais / Carcinoma de Células Escamosas / Neoplasias de Cabeça e Pescoço Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article